Vivek Ramaswamy’s crusade to change FDA could boost biotech, and himself
The Washington Post, November 25, 2024: This news article quotes NCHR and other experts explaining that Vivek Ramaswamy is a former biotech executive who is very critical of the FDA in ways that reflect his extensive conflicts of interest. If Donald Trump follows Ramaswamy's advice, Ramaswamy is likely to greatly increase his wealth and patients will be harmed by paying for expensive new medications that do not work.
The post Vivek Ramaswamy’s crusade to change FDA could boost biotech, and himself first appeared on National Center for Health Research.
The post Vivek Ramaswamy’s crusade to change FDA could boost biotech, and himself appeared first on National Center for Health Research.